For levothyroxine , patients should maintain consistent timing of administration (typically on an empty stomach) and thyroid function should be monitored after starting or stopping tirzepatide, as absorption changes may necessitate dose adjustments
Secondary outcome measurements included reduction in body weight from baseline by at least 5% or 10% by week 26, changes in waist circumference, total cholesterol, HDL, LDL, VLDL, and triglycerides, and levels of different glycemic variables including HbA1C, fasting plasma glucose, fasting insulin, insulin resistance, and the functioning of beta-cells
Zaina, if the bottle is 3ml (3000mcg) and your dosage is 250mcg, you would do 3000 divided by 250, which will give you 12
Cardiovascular effects warrant consideration